Business
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
EMERYVILLE, Calif., February 03, 2026--Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).
About this update from Estrella Immunopharma, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/d8f698dc58f4b9729b1eeac4885734ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QRJEtulCNV9BAEYCzUceHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d8f698dc58f4b9729b1eeac4885734ee","width":480,"height":480}},"lazy":false},{"type":"text","content":"EMERYVILLE, Calif., February 03, 2026--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).","length":541,"tagName":"p"},{"type":"text","content":"The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL).","length":214,"tagName":"p"},{"type":"text","content":"Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at www.tandemmeetings.com.","length":144,"tagName":"p"},{"type":"text","content":"Details of the Late-Breaking Oral Presentation:","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Final Paper Number: LBA-1","length":25,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Abstract ID & Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Session: Late Breaking Abstracts","length":32,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST","length":60,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presenting Author: Naseem Esteghamat, MD MS","length":43,"tagName":"p","attribs":{}}]}],"tagNa...